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1. INTRODUCTION {#hsr248-sec-0005}
===============

A patient‐reported outcome (PRO) is any health status report that is provided directly by the patient, without interpretation of the patient\'s response by a clinician or anyone else.[1](#hsr248-bib-0001){ref-type="ref"} Patient‐reported outcomes can take on a variety of forms, including measurements of symptom severity and/or health‐related quality of life (HRQoL).[2](#hsr248-bib-0002){ref-type="ref"} Patient‐reported outcomes with a symptomatic focus are of the utmost importance in cancer care. Many cancer‐related symptoms are associated with the disease, but some symptoms such as fatigue, neuropathy, and affective symptoms can also be caused by cancer therapy.[3](#hsr248-bib-0003){ref-type="ref"} Regardless of cause, when symptoms are not managed effectively, they can impact patients\' functional status, affect, and HRQoL.[4](#hsr248-bib-0004){ref-type="ref"}, [5](#hsr248-bib-0005){ref-type="ref"}, [6](#hsr248-bib-0006){ref-type="ref"}, [7](#hsr248-bib-0007){ref-type="ref"}, [8](#hsr248-bib-0008){ref-type="ref"}, [9](#hsr248-bib-0009){ref-type="ref"} Further, unrelieved symptoms can cause patients to interrupt or abandon treatment[10](#hsr248-bib-0010){ref-type="ref"}, [11](#hsr248-bib-0011){ref-type="ref"} or decrease adherence to treatment regimens.[12](#hsr248-bib-0012){ref-type="ref"}, [13](#hsr248-bib-0013){ref-type="ref"}, [14](#hsr248-bib-0014){ref-type="ref"}, [15](#hsr248-bib-0015){ref-type="ref"}, [16](#hsr248-bib-0016){ref-type="ref"}, [17](#hsr248-bib-0017){ref-type="ref"}, [18](#hsr248-bib-0018){ref-type="ref"}

As essential a role that symptom PROs play in multidisciplinary cancer care, barriers exist that may result in suboptimal symptom assessment. Outpatient clinics must balance the need for comprehensive symptom assessments, while minimizing patient burden. One method is to implement short symptom screener tools, followed by more comprehensive questions if the patient elicits a positive screen result; this may maximize symptom reporting while reducing clinic burden on both patients and clinicians.[19](#hsr248-bib-0019){ref-type="ref"}, [20](#hsr248-bib-0020){ref-type="ref"}, [21](#hsr248-bib-0021){ref-type="ref"}

Symptom screening may also have merits in the context of prospective observational studies. Unlike clinical trial patients, who are aware that they are potentially benefiting from specialized treatment regimens, patients enrolled in observational studies often perceive no direct benefits. These patients may lack motivation to complete long questionnaires---a burden that can be avoided with effective screening tools.

Although dysphagia (difficulty swallowing) is not one of the most prevalent symptoms in the general cancer population, it has high morbidity. Decreased HRQoL accompanies difficulty in eating or drinking.[22](#hsr248-bib-0022){ref-type="ref"}, [23](#hsr248-bib-0023){ref-type="ref"} In the extreme setting, severe dysphagia managed by nasogastric feeding can lead to sustained symptoms due to muscle atrophy.[24](#hsr248-bib-0024){ref-type="ref"}, [25](#hsr248-bib-0025){ref-type="ref"} Dysphagia is associated with malnutrition and a subsequent increased risk of infection.[22](#hsr248-bib-0022){ref-type="ref"} When dehydration occurs, renal failure and other adverse effects such as constipation are common, which can associate with impaired mental status and delirium.[22](#hsr248-bib-0022){ref-type="ref"}, [26](#hsr248-bib-0026){ref-type="ref"}, [27](#hsr248-bib-0027){ref-type="ref"}, [28](#hsr248-bib-0028){ref-type="ref"}, [29](#hsr248-bib-0029){ref-type="ref"} Mechanical obstructive tumors can lead to weight loss and shorter survival times.[30](#hsr248-bib-0030){ref-type="ref"}, [31](#hsr248-bib-0031){ref-type="ref"}, [32](#hsr248-bib-0032){ref-type="ref"}

Within certain cancer populations, dysphagia is highly prevalent: Dysphagia is observed in approximately 50% of head and neck patients[33](#hsr248-bib-0033){ref-type="ref"}, [34](#hsr248-bib-0034){ref-type="ref"}, [35](#hsr248-bib-0035){ref-type="ref"}; progressive dysphagia and/or odynophagia (pain upon swallowing) are the most common presenting symptoms in gastroesophageal cancer patients.[36](#hsr248-bib-0036){ref-type="ref"} Radiation‐induced dysphagia and odynophagia occur in patients receiving radiation to the chest or mediastinum (the central compartment of the thoracic cavity), often up to 2 months posttreatment.[37](#hsr248-bib-0037){ref-type="ref"}

The main goals of this study were (1) to develop a dysphagia screening tool for use in both observational study screening and routine symptom monitoring, (2) to compare the tool\'s sensitivity and specificity with gold‐standard tools in capturing dysphagia symptoms, and (3) to assess the feasibility and acceptability of implementing our dysphagia screener tool on an electronic tablet (Apple\'s iPad) in an outpatient clinic. Because we were devising screening tools for research purposes (observational study) and separately for routine symptom monitoring, we have discussed them separately in [Sections 2](#hsr248-sec-0006){ref-type="sec"} and [3](#hsr248-sec-0016){ref-type="sec"}, as phase 1 (research/observational study) and phase 2 (routine use).

2. METHODS {#hsr248-sec-0006}
==========

2.1. Study design and population {#hsr248-sec-0007}
--------------------------------

This study was approved by the Research Ethics Board of the University Health Network in Toronto, Ontario, Canada; informed consent was obtained from all participants. The purpose of the study was to develop dysphagia screening tools for prospective observational studies (phase 1) and for routine clinical care (phase 2). In both phases, an expert panel using a consensus approach[38](#hsr248-bib-0038){ref-type="ref"} reviewed potential screening and follow‐up questions for criterion, content, and construct validity, as well as feasibility, where possible, validated gold standards were chosen. The phases were performed at separate times, with phase 2 occurring after the end of phase 1 recruitment.

2.2. Stakeholder and expert panel for phases 1 and 2 {#hsr248-sec-0008}
----------------------------------------------------

Two panels were created because of the number of individuals required; individuals were randomly assigned to each panel (13 per panel), with one panel focused on phase 1 and the other panel on phase 2. Decisions of one panel were then introduced to the other panel for commentary and discussion. Individuals for the 2 panels included 3 gastrointestinal cancer clinic nurses from 2 Toronto institutions; 2 outpatient clinic nurses from institutions in Ottawa and Edmonton; 2 speech, swallowing, and language clinicians from Toronto and Houston; 2 PhD researchers focusing on esophageal and head and neck cancer translational research from Toronto and Vancouver; 1 PhD researcher focused on knowledge translational science (Calgary); 3 gastrointestinal cancer medical oncology fellows originally from 3 continents but currently training in Canada; 2 radiation oncology fellows from North America; 2 staff surgeons and 2 radiation oncologist staff; 3 medical oncology staff from 3 centers in North America; and 4 patient representatives, including one from the Canadian Cancer Society. There was 1 face‐to‐face initial meeting of a subset of both of these panels at the Canadian Clinical Trials Group Annual Meeting. Stakeholders then met in 2 formal 2‐hour virtual meetings, with further communications performed online through eletronic mail.

2.3. Statistical analyses {#hsr248-sec-0009}
-------------------------

Descriptive statistics were performed separately for phases 1 and 2, including median, minimum, and maximums for continuous variables, and frequency tabulations by categorial variables. All statistical analyses were completed using SAS 9.4.

### 2.3.1. Phase 1 screeners for research purposes {#hsr248-sec-0010}

In phase 1, when developing a screening tool useful for prospective observational studies, the primary objective was to identify a highly sensitive screening question for dysphagia to reduce the burden of completing the full validated FACT‐E swallowing index (45 total questions and 8 swallowing‐specific questions).[39](#hsr248-bib-0039){ref-type="ref"} The panel selected 2 potential single‐screening questions: Screener 1, "How are you currently eating?", was derived from O\'Rourke et al,[40](#hsr248-bib-0040){ref-type="ref"} with response choices of "normal," "eats soft food only," "eats pureed food only," "drinks liquid only," and "no swallowing at all" (Figure [2](#hsr248-fig-0002){ref-type="fig"}), and for screener 2, one of the FACT‐E questions itself was chosen as a putative screening question: "I can swallow easily and naturally," with response choices of "very much," "quite a bit," "somewhat," "a little bit," and "not at all." Given a gold standard based on FACT‐E that is focused on esophageal cancer patients, all phase 1 patients were restricted to those with a diagnosis of gastroesophageal cancer.

2.4. Recruitment and data collection procedures {#hsr248-sec-0011}
-----------------------------------------------

At outpatient clinics, patients were prescreened for study eligibility by the clinical team. Patients over the age of 18 years with a gastroesophageal or esophageal cancer, who were capable of communcating in English and were deemed to be competent to understanding the study by their physicians, were deemed eligible. A life expectancy by their physicians of at least 12 weeks was also an eligibility criterion, as the institutional review board felt that approaching actively dying patients was unethical. Eligible patients were approached in clinic waiting areas and examination rooms prior to their appointments. In phase 1, patients completed screeners 1 and 2 along with the 5‐question FACT‐E Swallowing Index subset.[39](#hsr248-bib-0039){ref-type="ref"} The full questionnaire included clinico‐demographic questions and the EQ5D‐3L, a 5‐question tool that can be converted into a health utility score.[41](#hsr248-bib-0041){ref-type="ref"} All patients included in phase 1 completed the questionnaire on paper. Cancer clinical data for patients was abstracted from the electronic medical records. Clinicians were not given the dysphagia data but were asked to manage their patients in a usual fashion.

2.5. Statistical analysis {#hsr248-sec-0012}
-------------------------

For phase 1, patients were considered screen‐positive if they responded anything other than "normal" to Screener 1 or "very much" to Screener 2 (see Figure [2](#hsr248-fig-0002){ref-type="fig"} for full response set). Sensitivities and specificities were calculated for each screener against various Swallowing Index Cut‐off Values (SICVs), a summation of scores from 5 FACT‐E questions (E1, E2, E3, E5, and HN7), with possible SICV values of 0 to 20; higher scores represented lower severity of symptoms. Negatively worded questions were reverse scored. Swallowing Index Cut‐off Values were determined from clinical factors previously described by Darling et al[39](#hsr248-bib-0039){ref-type="ref"}: scores of 5.5 (2 standard deviations below mean of surgical cancer patients at 3‐4 months follow‐up), 7.1 (1 standard deviation below mean of cancer patients who experienced weight loss), 12.16 (mean of cancer patients who experienced weight loss), 13.3 (mean of surgical cancer patients), 14.5 (mean of surgical cancer patients at 3‐4 months follow‐up), and 16.0 (mean of cancer patients without pain). Receiver operating characteristic curves were generated using the same screener and these various SICV criteria.

### 2.5.1. Phase 2 screeners for routine clinical monitoring {#hsr248-sec-0013}

In phase 2, the objective was to develop and evaluate practical, routine screening question(s) for detecting swallowing disturbances in routine cancer patient management. Similar to our previous evaluations,[42](#hsr248-bib-0042){ref-type="ref"} we used more comprehensive and focused symptom questions in the style of Patient Reported Outcomes for Common Terminology Criteria for Adverse Events (PRO‐CTCAE). However, while PRO‐CTCAE has a single question about dysphagia, our expert panel determined that for clinical management purposes, severity of symptoms and functional interference were both of clinical relevance; symptom frequency, however, was too confounded by a patient\'s frequency of attempts at eating. The panel also identified that difficulty swallowing (dysphagia) and pain upon swallowing (odynophagia) of solids, and independently, of liquids, were important separate symptoms requiring different management and should be assessed separately. In the first part of phase 2, the evaluation was, therefore, of 2 separate screening questions, 1 for dysphagia (screener 3) and 1 for odynophagia (screener 4), and initially tested on patients in this manner. Upon a suggestion at a prespecified mid--phase 2 stakeholder and expert panel meeting, the 2 screening questions were later combined into a single screening question (screener 5): "Do you experience any difficulty or pain upon swallowing?", with response choices of "no," "difficulty swallowing only," "pain swallowing only," and "both difficulty and pain swallowing"; the last half of the phase 2 section then utilized the 1 question screener (screener 5). With the purpose of screening for routine cancer care, dual assessments of feasibility/patient acceptability and sensitivity/specificity of the screener were performed. Given this same objective, patients with head and neck and gastroesophageal cancers, and those receiving mediastinal radiation, were chosen as test subjects. All PRO‐CTCAE data were dichotomized into no symptoms versus symptoms of any grade, in order to ensure that the screener questions could be sensitive enough to capture even subtle symptoms that could be addressed in follow‐up questions.

2.6. Recruitment and data collection procedures {#hsr248-sec-0014}
-----------------------------------------------

At outpatient clinics, patients were prescreened for study eligibility with the clinical team. Eligibility criteria were the same as phase 1, except inclusion was expanded to include individuals with a head and neck cancer, a gastroesophageal or esophageal cancer, or a lung cancer that was being treated primarily with radiation or chemoradiation; these diagnoses are associated with high prevalences of dysphagia and odynophagia.[43](#hsr248-bib-0043){ref-type="ref"}, [44](#hsr248-bib-0044){ref-type="ref"} Eligible patients were approached in clinic waiting areas and examination rooms prior to their appointments. The phase 2 electronic tablet--based questionnaire included either the 1‐question or 2‐question screener and the PRO‐CTCAE--like comprehensive panel of follow‐up questions (see Table [2](#hsr248-tbl-0002){ref-type="table"}, phase 2), a set of 9 questions designed to assess the feasibility and acceptability of implementing the survey in a clinical setting, clinico‐demographic questions, and the EQ5D‐3L. The total number of questions was 23 to 24, depending on whether the patient completed the 1‐question or 2‐question screener. Some phase 2 patients answered all the questions regardless of their answers to the screening questions, which allowed their data to be assessed for screener sensitivity/specificity. The remaining phase 2 patients only answered the follow‐up questions when they were screen‐positive; it was this latter set of patients that was administered the feasibility/acceptability survey. Cancer clinical data for patients was abstracted from the electronic medical records. Clinicians were not given the dysphagia data but were asked to manage their patients in a usual fashion.

2.7. Statistical analysis {#hsr248-sec-0015}
-------------------------

For phase 2, sensitivities and specificities were calculated for the 1‐question screener against the PRO‐CTCAE--like follow‐up questions. Using a strict definition, all follow‐up questions had to be answered in the negative ("none" or "not at all") for the patient to be considered to have either no dysphagia or no odynophagia (these 2 symptoms were assessed independently).

3. RESULTS {#hsr248-sec-0016}
==========

3.1. Phases 1 and 2 description {#hsr248-sec-0017}
-------------------------------

Demographic and clinical characteristics are presented in Table [1](#hsr248-tbl-0001){ref-type="table"}. Figure [1](#hsr248-fig-0001){ref-type="fig"} describes the recruitment and analysis details of the population, captured in a CONSORT diagram. Prevalence of dysphagia (Figure [2](#hsr248-fig-0002){ref-type="fig"}) based on screener questions was approximately 36% to 40%, regardless of whether it was assessed as the ability to eat (phase 1) or the presence of difficulty or pain upon swallowing (phase 2), and regardless of whether it was a 2‐question or 1‐question screener.

###### 

Clinico‐demographic characteristics of the patients

  Variables                        Phase 1            Phase 2
  -------------------------------- ------------------ ------------------
  N                                178                255
  Age in years: median (range)     68.7 (33.1‐84.0)   63.2 (21.5‐89.8)
  Sex: female                      43 (24%)           64 (25%)
  Married or living with partner   115 (68%)          173 (68%)
  Ethnicity                                           
  White                            145 (81%)          190 (75%)
  Asian                            17 (10%)           27 (11%)
  Other                            7 (4%)             16 (6%)
  Prefer not to answer             9 (5%)             22 (9%)
  Highest level of education                          
  Secondary or less                63 (35%)           82 (32%)
  Postsecondary                    113 (63%)          142 (56%)
  Prefer not to answer             2 (1%)             31 (12%)
  Disease site                                        
  Gastroesophageal                 178 (100%)         84 (33%)
  Head and neck                    0 (0%)             155 (61%)
  Thoracic                         0 (0%)             16 (6%)

![CONSORT and recruitment flow diagrams for swallowing difficulties assessment. For phase 1, the sensitivity and specificity were assessed for 2 potential screeners versus the FACT‐E swallowing index in gastroesophageal cancer patients. For phase 2, dual assessments of feasibility/patient acceptability (1‐question and 2‐question screeners) and sensitivity/specificity of the 1‐question screener versus a Patient Reported Outcomes for Common Terminology Criteria for Adverse Events (PRO‐CTCAE) gold standard. SICV, Swallowing Index Cut‐off Value](HSR2-1-e48-g001){#hsr248-fig-0001}

![Prevalence of phases 1 and 2 screener questions. Graphs illustrating screener response distribution for phase 1 and 2, separately. Nearly 40% of all patients in each phase were screen‐positive for dysphagia. For phase 1, screener 1 is reported. For phase 2, the 2‐question screeners used screeners 3 and 4, while the 1‐question screener used screener 5](HSR2-1-e48-g002){#hsr248-fig-0002}

Proper evaluation of a screening tool requires a broad distribution of patients with and without swallowing issues. As expected, both phases 1 and 2 patients reported difficulty swallowing solid foods more often than soft/mashed foods or liquids. The median summative SICV score was 17 (range: 2‐20); one‐quarter of patients fell below the 12.16 SICV, the mean value of patients who had suffered associated weight loss (Table [2](#hsr248-tbl-0002){ref-type="table"}).

###### 

Distribution of answers to comprehensive gold standard questions on dysphagia and odynophagia

                                                        Phase 1 (N = 178)                                    
  ----------------------------------------------------- ------------------- ---------- ---------- ---------- -----------
  "I have difficulty swallowing solid foods"            26 (15%)            25 (14%)   28 (16%)   31 (17%)   68 (38%)
  "I have difficulty swallowing soft or mashed foods"   6 (3%)              12 (7%)    25 (14%)   25 (14%)   110 (62%)
  "I have difficulty swallowing liquids"                4 (2%)              10 (6%)    13 (7%)    24 (13%)   127 (71%)
  "I choke when I swallow"                              2 (1%)              7 (4%)     16 (9%)    26 (15%)   127 (71%)
  "I can swallow naturally and easily"                  61 (34%)            40 (22%)   33 (19%)   25 (14%)   19 (11%)

                                                                           Phase 2 (*N* \> 90)[b](#hsr248-note-0002){ref-type="fn"}                                    
  ------------------------------------------------------------------------ ---------------------------------------------------------- ---------- ---------- ---------- ----------
  Severity of difficulty swallowing[a](#hsr248-note-0001){ref-type="fn"}   3 (2%)                                                     8 (6%)     45 (34%)   36 (27%)   42 (31%)
  Difficulty upon swallowing -- Solid food interference                    5 (4%)                                                     18 (15%)   22 (18%)   29 (24%)   45 (38%)
  Difficulty upon swallowing -- Fluids interference                        2 (2%)                                                     5 (5%)     5 (5%)     29 (31%)   53 (56%)
  Severity of pain swallowing[a](#hsr248-note-0001){ref-type="fn"}         1 (1%)                                                     8 (8%)     14 (15%)   16 (17%)   57 (50%)
  Pain upon swallowing -- Solid food interference                          1 (1%)                                                     8 (9%)     10 (11%)   14 (15%)   58 (64%)
  Pain upon swallowing -- Fluids interference                              0 (0%)                                                     6 (6%)     3 (3%)     16 (17%)   69 (73%)

For these questions on severity, the category levels (from left to right) are severe, very severe, moderate, mild, none.

Because not all patients were required to complete every component of phase 2, the sample size for each specific question ranged from 91 through 134 patients. Shaded boxes refer to the answer associated with lack of symptoms.

3.2. Sensitivity and specificity of phase 1 screening questions {#hsr248-sec-0018}
---------------------------------------------------------------

In phase 1, initial analysis found that screener 1, "How are you currently eating?", with anchoring responses of "Able to eat normally" and "Unable to swallow anything," had significantly better test characteristics (sensitivity/specificity) than screener 2, "I can swallow easily and naturally." Sensitivities and specificities were evaluated against various gold‐standard SICVs (Table [3](#hsr248-tbl-0003){ref-type="table"}). In screener 1, sensitivities ranged from 66% to 86%, and specificities ranged from 63% to 83%. Areas under the curve ranged from 0.752 to 0.885 (Figure [3](#hsr248-fig-0003){ref-type="fig"}). The sum of sensitivity and specificity was greatest when SICV of 12.16 was used as a gold standard cut‐off (80% sensitivity and 75% specificity).

###### 

Assessment of sensitivities and specificities of screening questions in phases 1 and 2[a](#hsr248-note-0004){ref-type="fn"}

  Phase 1: screener 1, "How are you currently eating"                                      
  ----------------------------------------------------- ------- ---- ----- ---- ---- ----- -----
  5.5                                                   3.9%    6    108   63   1    86%   63%
  7.1                                                   10.1%   15   106   54   3    83%   66%
  12.16                                                 25.3%   36   100   33   9    80%   75%
  13.3                                                  32.0%   44   96    25   13   77%   79%
  14.5                                                  37.6%   48   90    21   19   72%   81%
  16                                                    44.4%   52   82    17   27   66%   83%

  Phase 1: screener 2, "I can swallow naturally and easily"                                     
  ----------------------------------------------------------- ------- ---- ---- ---- ---- ----- -----
  5.5                                                         3.9%    3    98   73   2    71%   57%
  7.1                                                         10.1%   12   96   64   6    67%   60%
  12.16                                                       25.3%   30   85   48   15   67%   64%
  13.3                                                        32.0%   35   80   41   22   61%   66%
  14.5                                                        37.6%   40   78   33   27   60%   70%
  16                                                          44.4%   45   75   24   34   57%   76%

  Phase 2 single question screener: difficulty swallowing question                           
  ------------------------------------------------------------------ ---- ---- --- --- ----- ------
  None/not at all only in all subsequent questions vs all others     61   33   0   4   94%   100%

  Phase 2 single question screener: pain swallowing question                               
  ---------------------------------------------------------------- ---- ---- --- --- ----- -----
  None/not at all in all subsequent questions only vs all others   24   38   3   4   86%   93%

Abbreviation: SICV, Swallowing Index Cut‐off Value.

For phase 1, screener 1, response choices were "normal," "eats soft food only," "eats pureed food only," "drinks liquid only," and "no swallowing at all."

![Receiver operator curves for various cutoffs of the FACT‐E swallowing index (Swallowing Index Cut‐off Value \[SICV\]). Area under the curve (AUC) ranges from 0.752 to 0.885](HSR2-1-e48-g003){#hsr248-fig-0003}

3.3. Sensitivity and specificity, feasibility, and acceptaibility of phase 2 screening questions {#hsr248-sec-0019}
------------------------------------------------------------------------------------------------

In phase 2, sensitivity and specificity were evaluated only on the 1‐question screener (screener 5). When compared with the gold standard PRO‐CTCAE questions on severity and functional interference for both dysphagia and odynophagia, the sensitivities ranged from 86% to 94% for each of the follow‐up questions, while the specificities ranged from 93% to 100% (Table [3](#hsr248-tbl-0003){ref-type="table"}). The screener was slightly more sensitive and specific to difficulty swallowing than to pain swallowing (Table [3](#hsr248-tbl-0003){ref-type="table"}).

Feasibility and acceptability, and practicality of dysphagia symptom screening via electronic tablet, were assessed for both the 2‐question (screeners 3 and 4) and 1‐question (screener 5) dysphagia screeners based on responses of 208 of 255 total patients included in phase 2; missing results were because we selected a random sample for completion of this section. Not every patient was approached because of the added coordinator time to track and time patients, and of those who were asked to complete this section, 97% had complete data. Median completion time for the 2‐question screener and follow‐up questions was 127 seconds; this time was reduced to 107 seconds for the 1‐question screener. Over 90% of patients completing both versions of the screener were willing to complete the surveys on a touchscreen tablet, did not feel like completing the surveys made their clinic visit more difficult, and did not find the questions to be upsetting or distressful. Over 80% felt that completing the surveys was not time consuming and that the completion of the surveys was a useful method to communicate with their clinician. However, less than 20% of patients wished to see or keep a printout of their dysphagia assessments ([Figure S1](#hsr248-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#hsr248-sec-0020}
=============

This study successfully identified several dysphagia screener questions that have potential use in screening for both observational studies and routine symptom assessment. The phase 1 screener (screener 1) provided a solid base for further investigation into dysphagia screener tools. It yielded sensitivity greater than 80% versus FACT‐E at 3 SICVs (equal to 5.5, 7.1, and 12.16), suggesting that it is useful for screening for dysphagia in prospective observational studies. The 1‐question screener (screener 5) developed and analyzed during phase 2 of the study was not only highly sensitive and specific when compared with our gold standard (PRO‐CTCAE--like follow‐up questions) but was also feasible and acceptable for use in routine multidisciplinary care. When symptoms were in the mild through very severe range that is consistent with a need for clinical intervention, the sensitivity and specificity of the screener were high (\>85% all values). Further, the screener and follow‐up questions, on average, took less than 2 minutes to complete, suggesting that the tool is practical for implementation in busy outpatient cancer clinics. Our analysis of the feasibility/acceptability responses by patients provides strong evidence that the tool minimizes patient burden, is easy for patients to use and understand, and improves communication of dysphagia symptoms between patient and clinician. The phase 2 screener (screener 5) may be an effective way to accurately detect the presence and assess the extent of patients\' dysphagia symptoms without significantly increasing clinic burden.

Currently, PRO‐CTCAE v1.0 is becoming more prevalent for toxicity evaluation.[45](#hsr248-bib-0045){ref-type="ref"} However, this tool only contains a single swallowing item, and while this may be sufficient for gathering toxicity information, it may not be enough for clinical management of symptoms. Our 6 focused assessment questions balance between extensive toxicity assessment and symptom control. These questions distinguish differences in difficulty and pain upon swallowing and describe the extent of severity and functional interference due to symptoms. Further, our follow‐up is formatted in a PRO‐CTCAE style, which allows for easy integration and comparison with other PRO‐CTCAE items.

This study supports the findings of prior studies[19](#hsr248-bib-0019){ref-type="ref"}, [20](#hsr248-bib-0020){ref-type="ref"}, [21](#hsr248-bib-0021){ref-type="ref"} that suggest that short screener tools can effectively assess cancer‐related symptoms and reduce outpatient clinic burden. This study, however, is the only one, to our knowledge, to develop a highly sensitive and specific screening tool explicitly for dysphagia/odynophagia. While more than one‐third of patients included in this study responded positively to screeners for dysphagia, swallowing disturbances are often not assessed in an outpatient clinic setting. For example, outpatient cancer clinics in Ontario routinely assess symptoms with the Edmonton Symptom Assessment System[46](#hsr248-bib-0046){ref-type="ref"}; this tool collects data on 9 common cancer symptoms, but dysphagia and odynophagia are not included. Our results suggest that the chosen phase 2 single screener question will be a highly effective clinical monitoring tool.

A recent randomized clinical trial (RCT) by Basch et al[47](#hsr248-bib-0047){ref-type="ref"} reported increased overall survival in a randomized trial where the experimental arm had received rapid symptom screening (in the form of PRO‐CTCAE) and subsequent management, when compared with a control arm of patients receiving "usual" care. Thus, implementation of our screener routinely may have far‐reaching effects beyond improving HRQoL.

This study was not without limitations. Consenting patients were fluent in English, so this study does not suggest that our tool, as it currently exists, is generalizable to patients who speak other languages. Future validation in multiple languages would be important. In phase 1, we identified a screener question that would allow our patients to be dichotomized into those with and without dysphagia when using FACT‐E; we should caution that researchers who want to use the full scale of FACT‐E or analyze the data in a continuous manner should continue to use FACT‐E in its current state. Our study made no direct comparisons of the screener\'s effectiveness between the 3 groups included (head and neck, gastroesophageal cancers, and thoracic cancers undergoing radiation); however, the 1‐question screener was extremely straightforward and direct, so it is highly unlikely that the characteristics of our test would noticeably change across disease sites. We also did not assess clinician perceptions directly, as we tried to avoid clinician bias in influencing patient perception; instead, we avoided providing the clinicians with the dysphagia results completely and asked them to manage their patients in a usual fashion. Finally, there is still controversy as to whether the gold standard reporting of symptoms or toxicities should be "filtered" through a clinician\'s viewpoint (ie, physician interpretation of an open discussion of toxicities) or be directly ascertained from the patient using PROs; our study used the patient‐reported symptoms and toxicity as the gold standard.

Our study determined 2 highly sensitive (\>85% sensitivity phase 1 and \>90% sensitivity phase 2) screener questions for swallowing issues. One screener was designed for use in research settings, as it was designed for use instead of FACT‐E. The second screener was designed with a different purpose in mind: for routine clinical use. The screeners were neither burdensome on patients nor time consuming. Future studies should look to assess the practical implication of our screener in populations of non‐English--speaking patients in outpatient clinics. Comparison to other gold standard research tools for dysphagia should also be considered. In the meantime, we have established, in principle, the utility of implementing single‐question screeners in both the observational study setting and for routine clinical practice. We expect to reduce survey burden in patients by reducing the number of patients who need to complete the more extensive follow‐up questions that will refine the degree, frequency, and severity of symptoms required to manage these symptoms properly in the clinical setting.
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**SUPPLEMENTAL FIGURE 1.** Feasibility and acceptability responses for Phase 2 Screener. DY = definitely yes, PY = probably yes, NS = not sure, PN = probably not, DN = definitely not.
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